Goldman Sachs (GS) Analysts Downgrade Cepheid (CPHD) Shares to "Neutral"
Wednesday, July 06, 2021 9:00 AM

Equities research analysts at Goldman Sachs (NYSE: GS) downgraded shares of Cepheid (NASDAQ: CPHD) from a "buy" rating to a "neutral" rating in a research note to investors on Wednesday. The analysts currently have a $35.00 price target on the stock. The analysts noted that the move was a valuation call.

Separately, analysts at Piper Jaffray (NYSE: PJC) raised their price target on shares of Cepheid to $38.00 in a research note to investors on Thursday, June 23rd. Also, analysts at Zacks Investment Research reiterated a "neutral" rating on shares of Cepheid in a research note to investors on Tuesday, May 3rd. They now have a $34.00 price target on the stock.

Shares of Cepheid opened at 35.50 on Thursday. Cepheid has a 52 week low of $13.81 and a 52 week high of $35.70. The stock's 50-day moving average is $32.08 and its 200-day moving average is $28.00. The company has a market cap of $2.193 billion.

Cepheid last announced its quarterly results on Wednesday, April 20th. The company reported $0.01 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of ($0.01) EPS by $0.02. The company’s quarterly revenue was up 25.40% on a year-over-year basis. On average, analysts predict that Cepheid will post $0.02 EPS next quarter.

Cepheid is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the Clinical market, as well as for application in its legacy Biothreat, Industrial and Partner markets. Cepheid’s two principal systems are the GeneXpert and SmartCycler. The GeneXpert system integrates sample preparation in addition to deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and care units within hospitals and doctor’s offices. The GeneXpert system is also its system in the Biothreat market. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. In September 2009, the Company launched the GeneXpert Infinity System (Infinity) for high volume testing.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.